ARTICLE | Clinical News
Pollinex Quattro Birch: Ph III B301 started
March 17, 2017 1:03 PM UTC
Allergy Therapeutics began the double-blind, placebo-controlled, European Phase III B301 trial to evaluate 900, 2,400 and 6,000 standardized units/mL subcutaneous Pollinex Quattro Birch in about 562 p...
BCIQ Company Profiles